©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Divergent Mechanisms for Homologous Desensitization of p21 by Insulin and Growth Factors (*)

(Received for publication, July 14, 1995; and in revised form, August 2, 1995)

Jes K. Klarlund Andrew D. Cherniack Michael P. Czech

From the Program in Molecular Medicine, and Department of Biochemistry and Molecular Biology, University of Massachusetts Medical Center, Worcester, Massachusetts 01605

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Previous work suggested that desensitization of p21 in response to growth factors such as epidermal growth factor (EGF) results from receptor down-regulation. Here we show that p21 is desensitized by insulin in 3T3-L1 adipocytes in the continued presence of activated insulin receptors, while loss of epidermal growth factor and platelet-derived growth factor (PDGF) receptors in response to their ligands correlates with p21desensitization. Furthermore, elevated amounts of Grb2/Shc complexes persisted throughout p21 desensitization by insulin. However, immunoblotting of anti-Son-of-sevenless (Sos) 1 and 2 immunoprecipitates with anti-Grb2 antisera revealed that p21desensitization in response to insulin and PDGF, but not EGF, is associated with a marked decrease in cellular complexes containing Sos and Grb2 proteins. Nonetheless, the desensitization of p21in response to these stimuli was homologous, in that each peptide could reactivate [P]GTP loading of p21 after desensitization by any of the others. Taken together, these data indicate that insulin, EGF, and PDGF all cause disassembly of Sos proteins from signaling complexes during p21desensitization, but at least two mechanisms are involved. Insulin elicits dissociation of Sos from Grb2 SH3 domains, whereas EGF signaling is reversed by receptor down-regulation and Shc dephosphorylation, releasing Grb2 SH2 domains. PDGF action triggers both mechanisms of Grb2 disassembly, which probably operate in concert with GAP to attenuate p21 signaling.


INTRODUCTION

Peptide growth factors are key extracellular regulators that modulate pathways of intermediary metabolism, protein synthesis, and mRNA transcription. Growth factors also mediate critical steps in cell cycle control and DNA synthesis. This remarkable multitude and diversity of biological effects raises important questions about the molecular signaling mechanisms involved in the actions of these peptides. Recent work has revealed that several signaling pathways are simultaneously stimulated by growth factors, including the phosphoinositide cycle(1, 2, 3) , p21(4, 5, 6, 7, 8, 9, 10) , and the phosphatidylinositol 3-kinase reaction(11, 12, 13, 14) . These pathways initiate downstream events that must be highly coordinated, controlled, and ultimately extinguished to elicit appropriate types and duration of biological effects. Thus, understanding mechanisms that restrain these signaling circuits is an important aspect of the knowledge base required to fully describe them in molecular terms.

Cellular stimulation by peptide growth factors through small GTP binding proteins exemplifies the highly regulated nature of intermediary steps in signaling pathways. The p21 proteins cycle between the inactive, GDP-bound form and a GTP-bound, biologically active state through the actions of guanosine nucleotide exchange factors that catalyze release of GDP from p21, allowing GTP to bind, and GTPase activating proteins which enhance p21-bound GTP hydrolysis to GDP(4, 5, 6, 7, 8, 9, 10) . Growth factors and insulin are thought to activate p21 by recruitment of guanosine nucleotide exchange factors such as the Son-of-sevenless (Sos) (^1)1 and 2 to tyrosine-phosphorylated Shc proteins through the adaptor Grb2(15, 16, 17, 18, 19) . Grb2 binds to tyrosine phosphate on Shc (Tyr-317) through its src homology SH2 domain and binds proline-rich regions on Sos proteins through its SH3 domains(17, 20) . In the case of insulin but not EGF or PDGF, another tyrosine-phosphorylated protein, IRS-1, also binds Grb2 and may be involved in p21 activation(21, 22) . Rapid increases in GTP loading of p21 proteins in response to growth factors is followed by a deactivation phase whereby GTPbulletp21concentrations return to near basal levels(23, 24, 25, 26, 27) . Activated, GTP-bound p21 associates with the N-terminal, regulatory domain of Raf protein kinases, leading to events that elevate Raf kinase activity(28, 29, 30) . The Raf kinases in turn phosphorylate and activate MEK protein kinases, which further activate a cascade of protein kinases, including the MAP kinases(6, 28, 31, 32, 33, 34) . Importantly, MAP kinase activation by growth factors through this mechanism is also transient and returns to near basal levels with about the same time course as p21 deactivation(35, 36, 37, 38) . Thus, important feedback mechanisms operate to restrain this signaling pathway and control the extent of cellular modulation.

Previous work indicated that desensitization of p21 caused by EGF is associated with rapid disappearance of EGF receptors from the cell surface(39) , suggesting a simple mechanism for the desensitization. Consistent with the concept that EGF-mediated down-regulation of its specific receptors causes the loss of p21 responsiveness to EGF, insulin was found to reactivate p21 after desensitization by EGF(39) . However, interpretation of those studies is difficult because insulin itself did not elicit p21 desensitization under the conditions of the experiments. This was perhaps due to the use of a unique cell line heterologously expressing very high levels of human insulin receptors because we have recently reported marked p21 desensitization in response to insulin in 3T3-L1 adipocytes(40) . We and others have also found that insulin caused partial dissociation of Grb2bulletSos complexes, suggesting an alternative mechanism of deactivation(40, 41) . Furthermore, no detailed studies have appeared which evaluate the basis for PDGF-induced p21 desensitization. Thus, the aim of the present investigation was to characterize the molecular nature of p21 activation and deactivation in a well established model system, the 3T3-L1 adipocyte, that responds to insulin, EGF, and PDGF without overexpressed receptors.

We demonstrate here that insulin, EGF, or PDGF treatment of 3T3-L1 adipocytes causes a rapid desensitization of p21 following the initial activation phase, but that reactivation can be achieved by either of the two other peptides. Importantly, we show that insulin-mediated p21 desensitization occurs without loss of activated cell surface insulin receptors or Shc/Grb2 complexes, in contrast to EGF-mediated p21 desensitization. Furthermore, both insulin and PDGF cause disassembly of Grb2bulletSos complexes in these cells, while EGF does not. These data demonstrate that receptor down-regulation cannot explain the homologous p21desensitization caused by insulin and that regulation of Sos function through its dissociation from Grb2 by both insulin and PDGF may play an important role in this process.


MATERIALS AND METHODS

Cell Culture

3T3-L1 mouse fibroblasts were grown to confluence in Dulbecco's modified Eagle's medium with 10% calf serum, 50 units/ml penicillin, and 50 µg/ml streptomycin sulfate and were differentiated to adipocytes as described previously(42) . Adipocytes were used 9-14 days after the start of differentiation. Prior to stimulation with growth factors, cells were serum starved for 16-24 h in Dulbecco's modified Eagle's medium with 0.5% bovine serum albumin.

Antibodies

Anti-mSos antibody was raised against a peptide corresponding to amino acids 100-120 which are identical in mSos1 and mSos2(15) . Antiserum to mSos1 and 4G10 anti-phosphotyrosine antibody were from Upstate Biotechnology Incorporated. Monoclonal antibody to Grb2 and anti-phosphotyrosine (PY20) antibody were from Transduction Laboratories. Monoclonal anti-p21 antibody was obtained from supernatants of the hybridoma cell line Y13-259 (American Type Culture Collection).

Plasma Membrane Preparation

Plasma membranes were prepared from 3T3-L1 adipocytes in 15-cm plates as described previously(43) .

Ras Activation Assay

3T3-L1 adipocytes in 10-cm plates were incubated with 3.5 ml of phosphate-free Dulbecco's modified Eagle's medium with 25 mM HEPES, pH 7.4, 2 mM sodium pyruvate, and 1 mCi of carrier-free [P]orthophosphate at 37 °C. After 16 h, the cells were transferred to 22 °C for 30 min and stimulated for the indicated times with growth factors. The cells were then rapidly washed and lysed by addition of 800 µl of lysis buffer (20 mM Tris, pH 8.0, 100 mM NaCl, 1 mM MgCl(2), 1% Triton X-100, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, and aprotinin, pepstatin, and leupeptin at 0.5 µg/ml each with 10% tissue culture supernatant from the hybridoma cell line Y13-259). After clarification by centrifugation, the lysates were incubated for 1 h with 5 µl of Sepharose 4B coupled to goat anti-rat antibodies (Organon Teknika-Cappel). The beads were collected by centrifugation and washed extensively in 50 mM HEPES, pH 7.4, 0.5 M NaCl, 5 mM MgCl(2), 0.1% Triton X-100, and 0.005% sodium dodecyl sulfate. Bound GDP and GTP were eluted and subjected to chromatography on polyethyleneimine cellulose plates (Merck) as described with GDP and GTP as unlabeled markers(44) . The locations of the GDP and GTP were visualized by UV light, and relevant areas were cut out and the radioactivity was quantitated in a beta counter.

Cell Lysis, Immunoprecipitation, and Immunoblotting

After stimulation for the indicated times, the cells were washed in 10 ml of ice-cold phosphate-buffered saline (PBS: 1.8 mM KH(2)PO(4), 171 mM NaCl, 1.0 mM Na(2)HPO(4), and 3.4 mM KCl, pH 7.2) and lysed in 1 ml of cold lysis buffer (30 mM HEPES, pH 7.5, 100 mM NaCl, 1 mM EGTA, 1% Triton X-100, 2 mMp-nitrophenyl phosphate, 50 mM NaF, 1 mM Na(3)VO(4), 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml each of leupeptin, aprotinin, and pepstatin, and 1 mM benzamidine). The lysates were spun at 15,000 times g for 10 min at 4 °C. The supernatants were removed and assayed for total protein content using the Bradford (45) method. After normalization of protein, the lysates were then precleared by the addition of 10 µl of protein A-Sepharose (Pharmacia Biotech Inc.) and incubated on an end-over-end mixer at 4 °C for 1 h. Samples were then centrifuged at 15,000 times g for 2 min at 4 °C, and supernatants were incubated on an end-over-end mixer with 10 µl of antibody and 25 µl of protein A-Sepharose for 16 h. The Sepharose was pelleted by centrifugation at 15,000 times g for 2 min at 4 °C. Pellets were washed five times with cold wash buffer (PBS with 0.1% Triton X-100, 2 mMp-nitrophenyl phosphate, 50 mM NaF, 1 mM Na(3)VO(4)), and the protein was dissolved in SDS-PAGE sample buffer. Samples were analyzed by SDS-PAGE and transferred to nitrocellulose filters. Filters were probed with the indicated antibodies and bound antibody was visualized using Renaissance (DuPont NEN) according to the manufacturer's specifications. For visualization of the tyrosine phosphorylated insulin receptor, the anti-phosphotyrosine antibody 4G10 was used. For visualization of the EGF receptor, the anti-phosphotyrosine PY20 antibody was used, since the 4G10 antibody was found to react poorly with the tyrosine-phosphorylated EGF receptor.


RESULTS

Most studies on p21 regulation by insulin have been performed on cells overexpressing insulin receptors rather than primary fat or muscle cells. Cultured 3T3-L1 adipocytes were chosen for the present studies because they have been extensively used as a model system for insulin sensitive tissues and are highly responsive to the hormone. In order to characterize the dynamics of GTP loading of p21 in response to insulin, EGF, and PDGF in 3T3-L1 adipocytes, the GTP and GDP contents of p21 were determined at various times after addition of insulin, EGF (Fig. 1) or PDGF (Fig. 2) to P-labeled cells. These measurements were conducted at room temperature because greater responses to growth factors were observed compared to 37 °C. Nucleotides bound to p21 from [P]orthophosphate-labeled cells were analyzed by thin layer chromatography. GTP accounted for about 10% of total labeled GTP plus GDP in p21 immunoprecipitates from control cells ( Fig. 1and Fig. 2).


Figure 1: Stimulation and deactivation of GTP loading of p21 in response to insulin and EGF. 3T3-L1 fibroblasts in 10-cm plates were differentiated to adipocytes, labeled with [P]orthophosphate, and stimulated for various times with either 10M insulin or 10M EGF at 22 °C. p21 was immunoprecipitated, and the bound nucleotides were eluted and analyzed by chromatography on polyethyleneimine cellulose plates. A, autoradiography of plates. B, calculated ratio of [P]GTP/([P]GTP + [P]GDP) as a function of time.




Figure 2: Stimulation and deactivation of GTP loading of p21 in response to PDGF. 3T3-L1 fibroblasts in 10-cm plates were differentiated to adipocytes, labeled with [P]orthophosphate, and stimulated for various times with 10M PDGF. The relative content of GTP and GDP was determined as described in the legend for Fig. 1. A, autoradiography of plates. B, calculated ratio of [P]GTP/([P]GTP + [P]GDP) as a function of time.



Treatment of the cultured adipocytes with insulin, EGF, or PDGF caused a 2-3-fold increase in labeled GTP recovered from p21 immunoprecipitates within 5 min. A gradual decay in this effect was observed in the continued presence of these growth factors, resulting in the return of GTPbulletp21 concentrations to near basal levels by 120-180 min ( Fig. 1and Fig. 2). Interestingly, maximal [P]GTP loading of p21 in response to stimulation of 3T3-L1 adipocytes at 37 °C was also observed by 5 min, but the deactivation phase was much more rapid at the higher temperature (not illustrated). These data demonstrate that insulin, EGF, and PDGF cause similar stimulatory effects on steady-state GTP binding to endogenous p21 in these cells, followed by a decay to GTPbulletp21 levels approaching those observed in the basal state within 2-3 h at room temperature and 20-30 min at 37 °C.

It has been proposed (39) that receptor down-regulation accounts for p21 desensitization in response to EGF, based on the observed rapid loss of cell surface receptors that paralleled the deactivation of p21. However, certain receptor tyrosine kinases known to desensitize p21, such as the insulin receptor, recycle to the plasma membrane in response to ligand-mediated endocytosis, ensuring a high steady-state cell surface receptor content (46) . Experiments were designed to determine whether tyrosine-phosphorylated receptors in the plasma membrane of 3T3-L1 adipocytes remain at high levels during prolonged insulin, EGF, or PDGF treatment. As shown in Fig. 3, insulin receptor beta subunit, EGF, and PDGF receptors in plasma membranes were readily visualized by immunoblotting with anti-tyrosine phosphate antibody 5 min after incubation of cultured adipocytes with 100 nM insulin, 100 nM EGF or 10 nM PDGF, respectively. Little or no receptor tyrosine phosphorylation could be detected in the absence of these peptides. The level of tyrosine-phosphorylated insulin receptor in the plasma membrane fraction of 3T3-L1 adipocytes remained elevated throughout the 2-h incubation period during which p21 desensitization was observed (Fig. 3). In contrast, EGF or PDGF receptor tyrosine phosphorylation in response to EGF, and PDGF, respectively, markedly decreased during the 3-h p21 desensitization phase elicited by EGF or PDGF treatment (Fig. 3). These data indicate that EGF and PDGF receptor down-regulation or dephosphorylation correlates with p21 desensitization, whereas insulin receptors in the plasma membranes of cultured adipocytes remain tyrosine phosphorylated and active throughout the course of p21 desensitization.


Figure 3: Levels of tyrosine- phosphorylated insulin, EGF, and PDGF receptors in plasma membrane fractions of 3T3-L1 adipocytes. Plasma membranes from 3T3-L1 adipocytes were isolated after various times of stimulation with 10M insulin, 10M EGF, or 10M PDGF. The membrane proteins (6 µg/lane) were separated by SDS-PAGE using 6% gels, transferred to nitrocellulose, and blotted with anti-phosphotyrosine antibody. A comparison of the intensities of the signals from the insulin receptor by densitometry revealed no significant decrease from 5 min to 120 min of insulin stimulation (average of triplicate determinations).



In order to extend the results in Fig. 3, we reasoned that tyrosine phosphorylation of Shc proteins should correlate with the presence of activated receptors in the plasma membrane. Thus, for example, Shc tyrosine phosphorylation should be transient and decrease with a time course similar to the loss of activated EGF receptors from plasma membranes. This should be accompanied by dissociation of Grb2 from Shc. This was tested by immunoprecipitation of Shc proteins from lysates of 3T3-L1 adipocytes treated with insulin or EGF for various times. As shown in Fig. 4, immunoblotting such Shc immunoprecipitates after SDS-PAGE with anti-Grb2 antiserum revealed both insulin and EGF rapidly increased the amount of Grb2 associated with Shc. In the case of insulin stimulation, the amount of Grb2 in Shc complexes remain elevated for 2 h. In contrast, complexes containing Shc and Grb2 formed in response to EGF receptor activation are mostly dissociated during the time course of p21 desensitization. The time course of this disassembly is consistent with the hypothesis that it constitutes, at least in part, an underlying mechanism of p21 desensitization in response to EGF.


Figure 4: Association of Grb2 with Shc proteins in cultured adipocytes. 3T3-L1 adipocytes were stimulated with either 10M insulin or 10M EGF for the indicated times. The cells were then lysed, and 500 µg of total cell protein was immunoprecipitated with 2 µg of Shc antibody. A quarter of the precipitates were separated by SDS-PAGE, transferred to nitrocellulose, and blotted with antibodies to Grb2. A, autoradiography of the blots. NI is precipitation of extracts from the 30 min time points with a non-immune serum. NE is mock precipitation using the anti-Shc antibody, but no extract. B, quantification of Grb2 in the immunoprecipitates by densitometry. The data were normalized to the initial stimulated level of Grb2 (10 min) and were compiled from two experiments.



The results indicating that Grb2 proteins remain associated with Shc during insulin-mediated p21 desensitization prompted us to examine the interaction of Grb2 and Sos proteins under these conditions. It was recently shown that insulin causes disassembly of Sos from Grb2 during p21 desensitization(40, 41) . Cultured 3T3-L1 adipocytes were incubated at 37 °C with or without insulin, EGF, or PDGF for 20 min to cause p21 desensitization. Lysates were immunoprecipitated with rabbit anti-mSos antibodies raised against a peptide corresponding to an N-terminal region of murine mSos1 that is identical to mSos2. Immunoblot analysis of such immunoprecipitates with anti-mSos1 antibodies specific to that isoform revealed equivalent amounts of mSos1 present in the lysates under all experimental conditions (Fig. 5). Treatment of cells with insulin, EGF, or PDGF caused a shift in electrophoretic migration of mSos1 proteins, reflecting hyperphosphorylation on serine and threonine residues(23, 47) . Immunoblotting of the anti-mSos precipitates with anti-Grb2 antibodies revealed Grb2 associated with Sos proteins (Fig. 5B). Importantly, insulin- and PDGF-mediated p21 desensitization was associated with a marked decrease in Grb2 content in these Sos immunoprecipitates. PMA, which also causes Sos hyperphosphorylation, mimicked the ability of insulin or PDGF to dissociate Grb2 from Sos (Fig. 5). In contrast, EGF action failed to cause a detectable reduction in complexes containing Sos and Grb2 proteins. Densitometry of the autoradiographs from several such experiments demonstrated a mean inhibition by insulin, PDGF, and PMA of about 60% in the amount of Grb2 protein that is associated with mSos proteins (Fig. 5C).


Figure 5: Disassembly of Grb2 from Sos in response to treatment of 3T3-L1 adipocytes with insulin, PDGF, or PMA but not EGF. A-C show immunoprecipitates from lysates of untreated control cells (CON) and cells that were stimulated for 20 min with 10M insulin (INS), 10M EGF, 10M PDGF, or 10M PMA. A, equal parts of the immunoprecipitates were separated by reducing SDS-PAGE (6% gel), transferred to nitrocellulose, and blotted with mSos1 antibody. B, equal parts of the immunoprecipitates were separated by reducing SDS-PAGE (12% gel), transferred to nitrocellulose, and blotted with Grb2 antibody. C, quantification of the amounts of Grb2 in mSos immunoprecipitates by densitometry. Data from insulin- and EGF-stimulated cells represent three independent experiments performed in duplicate. Data for PMA and PDGF treatment represent two independent experiments performed in duplicate. The results are normalized to the amount of Grb2 in unstimulated cells.



The fact that p21 desensitization due to insulin and PDGF action appears associated with the disassembly of cellular Grb2bulletSos complexes suggested a desensitization mechanism that may be general rather than selective. On the other hand, EGF-mediated deactivation might be expected to block the action of EGF specifically, based on the rapid down-regulation of its specific receptors. These hypotheses were tested by prolonged stimulation of P-labeled 3T3-L1 adipocytes with either EGF, PDGF, or insulin to cause activation and deactivation of p21 proteins, followed by a further addition of either of the three growth factors alone. Fig. 6shows, as expected, that 3T3-L1 cells treated with EGF for 3 h at 22 °C failed to display increased [P]GTP loading of p21 in response to a second addition of EGF, but did respond to insulin treatment. PDGF could also reactivate p21 after its desensitization to EGF (Fig. 7). Surprisingly, the desensitization of p21 mediated by insulin action was also homologous. Thus, prior prolonged treatment of the cultured adipocytes with insulin blocked p21 activation due to further addition of insulin, while EGF (Fig. 6) or PDGF (Fig. 7) treatment of such cells caused reactivation of p21. The increase in [P]GTP binding to p21 proteins caused by insulin, EGF, or PDGF in homologously desensitized cells was as great as in control adipocytes ( Fig. 6and Fig. 7).


Figure 6: Effects of insulin or EGF treatment of 3T3-L1 cells on GTP loading of p21 and their responsiveness to a subsequent incubation with the peptides. Cells were labeled with [P]orthophosphate as in Fig. 1and were treated or not with 10M EGF or 10M insulin at 22 °C. After 2 h (insulin-stimulated cells) or 3 h (EGF-stimulated cells), the cells were treated again with the same concentrations of hormones for 5 min as indicated in the figure. The nucleotide load on p21 was then determined. A, autoradiography of plates. B, the measured [P]GTP content in p21immunoprecipitates under various conditions. The data are from two experiments and are normalized to the amount of GTP in unstimulated cells. The values are means of triplicate or quadruplicate determinations, and the error bars represent the standard deviations.




Figure 7: Effects of treatment of 3T3-L1 cells with PDGF, EGF, or insulin on their responsiveness to a subsequent incubation with peptides. Cells were labeled with [P]orthophosphate as in Fig. 1and were treated or not with 10M PDGF, 10M EGF, or 10M insulin at 22 °C. After 2 h (insulin-stimulated cells) or 3 h (EGF- and PDGF-stimulated cells), the cells were treated with the same concentrations of peptides for 5 min as indicated in the figure. The nucleotide load on p21 was then determined. A, autoradiography of plates. B, the measured [P]GTP content in p21 under various conditions. The values are means of four to eight determinations from three separate experiments, and the error bars represent the standard deviations.



The data in Fig. 7show that desensitization of p21 by PDGF is also readily reversed by EGF or insulin. The stimulation of [P]GTP binding to p21 by EGF or insulin is similar in magnitude whether or not p21 desensitization to PDGF was first accomplished. Thus, for all combinations of growth factors used in this study, p21 desensitization is homologous in that the initiating growth factor is unable to maintain high cellular levels of GTPbulletp21, while all others can reactivate GTP binding to the proto-oncogene. Furthermore, homologous desensitization of p21 occurs whether or not activated receptors are maintained in the cell surface membrane and whether or not a portion of the cellular Grb2bulletSos complexes are dissociated. To confirm this latter point, P-labeled 3T3-L1 adipocytes were treated with PMA under conditions (see Fig. 5) where about 60% of the Sos proteins were dissociated from Grb2 and the p21 activation by growth factors was assessed. As shown in Fig. 8, PDGF, EGF, or insulin added to such PMA-treated cells were fully able to cause GTP loading of p21. Thus, disassembly of about 60% of the cellular Grb2bulletSos complexes is not sufficient to prevent acute activation of p21 by insulin, EGF, or PDGF.


Figure 8: Activation of p21 by growth factors after partial dissociation of Grb2bulletSos complexes induced by PMA. Adipocytes were treated with 1 µM PMA for 30 min, and then for 5 min with or without 10M insulin, 10M EGF, or 10M PDGF as indicated. The cells were then lysed, and the nucleotide load on p21 was determined. The values are means of four determinations from two separate experiments, and error bars represent the standard deviations.




DISCUSSION

Stimulated GTP loading of p21 proteins by growth factors is now well established as a key signaling element in their enhancement of cell proliferation(4, 5, 6, 7, 8, 9, 10) . The potent activation of protein kinases(28, 31, 32, 33, 34, 48) and the strong biological responses elicited by cellular p21bulletGTP complexes dictates the need for finely tuned regulatory mechanisms eliciting reversal of these effects. Consistent with results on the actions of growth factors in other cell types(23, 24, 25, 26, 27) , we observe a marked deactivation phase of p21 proteins after their enhanced GTP loading in response to EGF, PDGF, or insulin in 3T3-L1 adipocytes ( Fig. 1and Fig. 2). EGF and PDGF were more effective in stimulating levels of p21bulletGTP (3-fold) than was insulin (2-fold) at 22 °C in these cells, and the deactivation phase was somewhat slower during treatment with EGF or PDGF (3 h) versus insulin (2 h). However, in all cases, the cellular concentrations of p21bulletGTP fell to levels approaching those measured under basal conditions ( Fig. 1and Fig. 2), indicating the operation of a strong desensitization process. This was confirmed by the observation that readdition of the growth factor that had initiated the p21 activation and deactivation phases resulted in no further stimulation ( Fig. 6and Fig. 7).

Experiments with 3T3-L1 adipocytes performed at 37 °C showed more rapid desensitization phases for both insulin and EGF treatment, which were complete within 30 min of initial incubation with peptide (not illustrated). Desensitization at 37 °C led to levels of p21bulletGTP that were not significantly different than those measured in untreated adipocytes. Furthermore, this rapid time course of p21 activation and deactivation observed at 37 °C paralleled that of the activation and deactivation phases for MAP kinase activity in response to insulin or EGF in 3T3-L1 cells (49 and data not shown). Taken together, these data demonstrate that effective cellular mechanisms operate in this cultured adipocyte model system to limit the duration of maximal p21 signaling in response to insulin and growth factors.

A recent report suggested that little deactivation and desensitization of p21 occurs in response to insulin treatment of transfected cultured cells overexpressing insulin receptors(39) . In contrast, our present results show unequivocal p21 desensitization during prolonged incubation of 3T3-L1 adipocytes with insulin ( Fig. 1and Fig. 6). Furthermore, more recent work in our laboratory has demonstrated insulin-mediated p21 desensitization in primary rat adipocytes as well (not illustrated). The failure to observe p21 desensitization in response to insulin in the previous study (39) probably reflects the different cell types used. Cells expressing high levels of insulin receptors were employed in those studies. Experiments in our laboratory show that Chinese hamster ovary cells expressing human insulin receptors at high levels also exhibit both activation and deactivation phases with respect to GTP loading of p21 upon insulin treatment (not illustrated). Thus it is unlikely that heterologous expression of insulin receptors in cultured cells eliminates the desensitization phenomenon, although perhaps extraordinarily high levels of insulin receptors used in the previous study (39) may account for the difference in results.

It has been suggested that p21 desensitization occurs through specific down-regulation of growth factor receptors based on studies with EGF(39) . In those experiments, EGF-mediated p21 desensitization was accompanied by rapid disappearance of cell surface EGF receptors, as detected by binding of cells to labeled EGF peptide. The present work demonstrates that stimulated GTP loading of p21 can be reversed and p21 desensitized even in the continued presence of activated receptors ( Fig. 1and Fig. 3). Our experimental approach took advantage of the fact that relatively pure preparations of plasma membranes can be prepared from adipocytes(40, 50) . Tyrosine-phosphorylated EGF, PDGF, or insulin receptors are readily identified in these membranes very rapidly after treatment of the intact cells with growth factors by SDS-PAGE and immunoblotting with anti-tyrosine phosphate antibody (Fig. 3). Three hours after incubation of cultured adipocytes with EGF or PDGF, tyrosine-phosphorylated EGF or PDGF receptors, respectively, were greatly diminished, while tyrosine-phosphorylated insulin receptors remained in these plasma membranes at high levels. These data are consistent with extensive literature documenting the rapid cellular internalization and degradation of EGF and PDGF receptors in response to their respective ligands(51, 52, 53, 54, 55, 56, 57, 58, 59) , and the rapid recycling of insulin receptors back to the cell surface during insulin treatment (46, 60, 61) . The present data, in combination with results of others, show that the decay of EGF or PDGF action on p21 under the conditions of our experiments could result from loss of their functional cell surface receptors, but this mechanism cannot explain p21 deactivation in response to insulin.

A major pathway of p21 activation appears to be phosphorylation of Shc proteins at tyrosine 317, which in turn binds the SH2 domain of Grb2(20, 47, 62, 63, 64, 65) . Shc proteins, which contain an SH2 domain and a domain with sequence similarity to collagen, are the products of a single gene that apparently gives rise to multiply spliced mRNA transcripts(63) . Upon its activation and autophosphorylation in response to EGF, the EGF receptor binds the SH2 domain of Shc directly through its phosphorylated tyrosines 1173 and 992. Activated EGF receptors also bind Grb2 directly through phosphorylated tyrosines 1068 and 1086. Activated insulin and PDGF receptors do not appear to directly bind Shc or Grb2, but initiate tyrosine phosphorylation of Shc through an unknown mechanism(64, 65) . This same alternate mechanism may be shared by EGF receptors because the latter can cause Shc tyrosine phosphorylation even when the tyrosines on the receptor are removed(66, 67) . Thus, EGF receptors can apparently act to mobilize Sos proteins through direct binding of Grb2 or Shc, and by an independent pathway leading to Shc phosphorylation. These considerations may explain the observation that GTP loading of p21 is enhanced more markedly by EGF than by insulin (Fig. 1). Similarly, the time course of EGF-mediated p21 desensitization is longer than that for insulin (Fig. 1). Consistent with this concept, the present studies show Shc association with Grb2 is more pronounced in response to EGF than insulin at the earliest time point measured in 3T3-L1 adipocytes (Fig. 4).

The time course of Shc/Grb2 association in response to EGF and insulin (Fig. 4) further confirm the postulate that EGF receptors rapidly down-regulate while insulin receptors remain active. The extensive decline in Grb2 associated with Shc after EGF stimulation apparently reflects a decrease in Shc tyrosine phosphorylation state. Insulin action, on the other hand, is not associated with a decrease in cellular Grb2/Shc complexes following the initial stimulation of complex formation observed at 10 min. Tyrosine phosphatase activity is presumably responsible for Shc dephosphorylation during loss of active EGF receptors, although the tyrosine phosphatase involved is not known. In any case, these results provide an independent confirmation that a decay in relevant tyrosine phosphorylation (EGF receptors and Shc) correlates with p21 desensitization caused by EGF, but not insulin. Thus, as shown in Fig. 9, the activation complex containing EGF receptor, Shc, and Grb2bulletSos proteins is hypothesized to disassemble during desensitization, yielding dephosphorylated (and degraded) EGF receptor, dephosphorylated Shc, and released Grb2bulletSos complexes. According to this model (Fig. 9, bottom), all of these components are removed from the plasma membrane, while p21 remains. PDGF receptor down-regulation also occurs in response to PDGF, and thus PDGF-mediated desensitization would be expected to be similar to the EGF system in this respect. In contrast, our data indicate that Sos proteins disengage from p21 in response to insulin while ShcbulletGrb2 complexes remain present (Fig. 9, top). PDGF is also able to cause disassembly of SosbulletGrb2 complexes (Fig. 5), suggesting that disengagement of both SH2 and SH3 domains of Grb2 from Shc and Sos, respectively, occurs in response to PDGF.


Figure 9: Hypothetical protein complexes involved in the activation and desensitization of p21 by insulin and EGF. In this model, both insulin and EGF cause Sos to bind to tyrosine-phosphorylated Shc, allowing it to interact with p21 at the plasma membrane. In the case of insulin action on 3T3-L1 adipocytes, the continued presence of activated insulin receptors ensures that Shc is maintained in its tyrosine-phosphorylated state, and desensitization hypothetically occurs by Sos dissociation from Grb2 in the complexes. Prolonged EGF treatment causes disassembly of Sos-containing complexes by a different mechanism. Upon down-regulation of the EGF receptor, Shc is released from the receptor. Shc is dephosphorylated, leading to dissociation of Grb2-Sos from Shc in the membrane. Thus, EGF receptors, Shc, and Grb2bulletSos are removed from plasma membrane-bound p21. These mechanisms presumably operate in conjunction with GAP activities to attenuate p21activation.



The disassembly of Sos from Grb2 complexes during insulin- and PDGF-mediated p21 desensitization may reflect an important feedback mechanism elicited by a protein kinase or kinases. Sos is known to be hyperphosphorylated in response to insulin (68) or EGF (69) , and PDGF also causes this effect as indicated in Fig. 5A by the shift in electrophoretic mobility of Sos on SDS-PAGE. We previously reported that at least two of the sites phosphorylated in heterologously expressed Drosophila Sos protein in intact cells matched sites phosphorylated in vitro by MAP kinase(70) . Phosphorylation of the yeast (Saccharomyces cerevisiae) CDC25 Ras exchange factor has also been reported to correlate with release of this protein from the plasma membrane and Ras deactivation(71) . Recently, it was proposed that MAP kinase phosphorylation of Sos results in its dissociation from Grb2. However, a key finding presented in this study is the failure of EGF to cause Sos dissociation from Grb2 (Fig. 5), in spite of its ability to cause Sos hyperphosphorylation. Both insulin and EGF cause similar stimulations of MAP kinases in 3T3-L1 adipocytes (49 and data not shown). These considerations indicate that phosphorylation of Sos by MAP kinases is not sufficient to cause disassembly of Grb2bulletSos complexes. Perhaps a unique protein kinase or kinases are stimulated by insulin and PDGF and cause Sos phosphorylation on a unique site that regulates Grb2 binding. This hypothesis will require further testing. Protein kinase C or protein kinases activated in response to protein kinase C stimulation by PMA appear to catalyze this response as well (Fig. 5).

The fact that only about 60% of the cellular Grb2bulletSos complexes are dissociated during p21 desensitization in response to insulin raises interesting questions about the role of this disassembly in p21 desensitization. Insulin increases GTP loading of p21 in 3T3-L1 adipocytes by only about 2-fold, followed by a return to basal levels ( Fig. 1and Fig. 6). Thus, the magnitude of the decrease in SosbulletGrb2 complexes in response to prolonged insulin treatment approximately coincides with the extent of decrease in GTPbulletp21 levels during deactivation and desensitization. The amount of ShcbulletGrb2bulletSos complexes present at the plasma membrane probably reflects an equilibrium involving the concentration of tyrosine-phosphorylated Shc and concentration of available SosbulletGrb2 complexes. In the case of insulin action, activated receptors and tyrosine-phosphorylated Shc, reflected by ShcbulletGrb2 complexes (Fig. 4), remain elevated during prolonged treatment, but SosbulletGrb2 complexes are decreased by about half. This results in an expected decrease in plasma membrane Sos that matches the decreased GTPbulletp21 levels. Thus insulin-mediated dissociation of Sos from Grb2 can account quantitatively for p21 deactivation, and desensitization could result because no further increase in insulin receptor phosphorylation occurs upon adding more insulin.

If p21 is desensitized to insulin by decreased Grb2bulletSos complexes, how do EGF and PDGF reactivate p21 under these conditions? One possibility is that these growth factors cause highly elevated levels of tyrosine phosphorylated Shc that effectively recruits SosbulletGrb2 complexes from the remaining pool. This explanation would be particularly satisfactory if EGF and PDGF normally elicit much higher levels of tyrosine phosphorylated Shc than are required for the 3-fold activation of p21. This may be the case because EGF treatment for 10 min is observed to cause much greater recruitment of Grb2 to Shc than does insulin (Fig. 4). Thus, EGF may be able to cause recruitment of sufficient ShcbulletGrb2bulletSos complexes even after depletion of about half of the cellular Grb2bulletSos complexes due to insulin action. It is also possible that specific cellular pools of Sos/Grb2 are subject to insulin-mediated dissociation, leaving other pools available for reactivation of p21 by EGF or other external stimuli. Alternatively, EGF and PDGF may recruit a different exchange factor or factors such as the newly reported C3G protein(72) . Further experiments are required to definitively link the Grb2/Sos disassembly observed here to the p21 desensitization mechanism. However, the data presented here and elsewhere (40) by our laboratory strongly implicate a link between these two processes. It is also likely that additional mechanisms, presumably involving GAP func-tion, act in concert with receptor down-regulation and Sos/Grb2 disassembly to attenuate p21 signaling.


FOOTNOTES

*
This work was supported by Grant DK30648 from the National Institutes of Health (to M. P. C.) and a postdoctoral fellowship from the Juvenile Diabetes Foundation International (to A. D. C.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

(^1)
The abbreviations used are: Sos, son-of-sevenless; EGF, epidermal growth factor; PDGF, platelet-derived growth factor; PAGE, polyacrylamide gel electrophoresis; PMA, phorbol 12-myristate 13-acetate.


ACKNOWLEDGEMENTS

We thank Judy Kula for excellent assistance in preparing the manuscript. Peptide synthesis for antibody production was performed by the Peptide Core Facility at the University of Massachusetts Diabetes and Endocrinology Research Center. We are grateful to Dr. Jeffrey E. Pessin for communicating results prior to publication.


REFERENCES

  1. Berridge, M. J., and Irvine, R. F. (1984) Nature 312,315-321 [Medline] [Order article via Infotrieve]
  2. Nishizuka, Y. (1984) Nature 308,693-698 [Medline] [Order article via Infotrieve]
  3. Pike, L. J. (1992) Endocr. Rev. 13,692-706 [Abstract]
  4. Burgering, B. M., Pronk, G. J., Medema, J. P., van der Voorn, L., de Vries Smits, A. M., van Weeren, P. C., and Bos, J. L. (1993) Biochem. Soc. Trans. 21,888-894 [Medline] [Order article via Infotrieve]
  5. Feig, L. A. (1994) Curr. Opin. Cell Biol. 6,204-211 [Medline] [Order article via Infotrieve]
  6. Khosravi-Far, R., and Der, C. J. (1994) Cancer Metastasis Rev. 13,67-89 [Medline] [Order article via Infotrieve]
  7. Lowy, D. R., and Willumsen, B. M. (1993) Annu. Rev. Biochem. 62,851-891 [CrossRef][Medline] [Order article via Infotrieve]
  8. McCormick, F. (1994) Curr. Opin. Gen. Dev. 4,71-76 [Medline] [Order article via Infotrieve]
  9. Medema, R. H., and Bos, J. L. (1993) Crit. Rev. Oncog. 4,615-661
  10. Moodie, S. A., and Wolfman, A. (1994) Trends Genet. 10,44-48 [CrossRef][Medline] [Order article via Infotrieve]
  11. Fry, M. J., and Waterfield, M. D. (1993) Phil. Trans. Royal Soc. Lond. B 340,337-344
  12. Parker, P. J., and Waterfield, M. D. (1992) Cell Growth & Differ. 3,747-752
  13. Soltoff, S. P., Carpenter, C. L., Auger, K. R., Kapellar, R., Schaffhausen, B., and Cantley, L. C. (1992) Cold Spring Harbor Symp. Quant. Biol. 57,75-80 [Medline] [Order article via Infotrieve]
  14. Varticovski, L., Harrison-Findik, D., Keeler, M. L., and Susa, M. (1994) Biochim. Biophys. Acta 1226,1-11 [Medline] [Order article via Infotrieve]
  15. Buday, L., and Downward, J. (1993) Cell 73,611-620 [Medline] [Order article via Infotrieve]
  16. Chardin, P., Camonis, J. H., Gale, N., Van Aelst, L., Schlessinger, J., Wigler, M. H., and Bar-Sagi, D. (1993) Science 260,1338-1343 [Medline] [Order article via Infotrieve]
  17. Downward, J. (1994) FEBS Lett. 338,113-117 [CrossRef][Medline] [Order article via Infotrieve]
  18. Egan, S. E., Giddings, B. W., Brooks, M. W., Buday, L., Sizeland, A. M., and Weinberg, R. A. (1993) Nature 363,45-51 [CrossRef][Medline] [Order article via Infotrieve]
  19. Schlessinger, J. (1994) Curr. Opin. Gen. Dev. 4,25-30 [Medline] [Order article via Infotrieve]
  20. Sasaoka, T., Rose, D. W., Jhun, B. H., Saltiel, A. R., Draznin, B., and Olefsky, J. M. (1994) J. Biol. Chem. 269,13689-13694 [Abstract/Free Full Text]
  21. Baltensperger, K., Kozma, L. M., Cherniack, A. D., Klarlund, J. K., Chawla, A., Banerjee, U., and Czech, M. P. (1993) Science 260,1950-1952 [Medline] [Order article via Infotrieve]
  22. Myers, M. G., Jr., Sun, X. J., and White, M. F. (1994) Trends Biol. Sci. 19,289-294 [CrossRef]
  23. Buday, L., and Downward, J. (1993) Mol. Cell. Biol. 13,1903-1910 [Abstract]
  24. Duronio, V., Welham, M. J., Abraham, S., Dryden, P, and Schrader, J. W. (1992) Proc. Natl. Acad. Sci. U. S. A. 89,1587-1591 [Abstract]
  25. Gibbs, J. B., Marshall, M. S, Scolnick, E. M., Dixon, R. A. F., and Vogel, U. S. (1990) J. Biol. Chem. 265,20437-20442 [Abstract/Free Full Text]
  26. Nakafuku, M., Satoh, T., and Kaziro, Y. (1992) J. Biol. Chem. 267,19448-19454 [Abstract/Free Full Text]
  27. Satoh, T., Endo, M., Nakafuku, M., Akiyama, T., Yamamoto, T., and Kaziro, Y. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,7926-7929 [Abstract]
  28. Marshall, C. J. (1994) Curr. Opin. Gen. Dev. 4,82-89 [Medline] [Order article via Infotrieve]
  29. McCormick, F. (1994) Trends Cell Biol. 4,347-350 [CrossRef]
  30. Williams, N. G., and Roberts, T. M. (1994) Cancer & Metastasis Rev. 13,105-116
  31. Blenis, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90,5889-5892 [Abstract]
  32. Cohen, P. (1993) Biochem. Soc. Trans. 21,555-567 [Medline] [Order article via Infotrieve]
  33. Crews, C. M., and Erikson, R. L. (1993) Cell 74,215-217 [Medline] [Order article via Infotrieve]
  34. Johnson, G. L., and Vaillancourt, R. R. (1994) Curr. Opin. Cell Biol. 6,230-238 [Medline] [Order article via Infotrieve]
  35. Peraldi, P., and Van Obberghen, E. (1993) Eur. J. Biochem. 218,815-821 [Abstract]
  36. Ray, L. B., and Sturgill, T. W. (1987) Proc. Natl. Acad. Sci. U. S. A. 84,1502-1506 [Abstract]
  37. Sun, H., Charles, C. H., Lau, L. F., and Tonks, N. K. (1993) Cell 75,487-493 [Medline] [Order article via Infotrieve]
  38. Ward, Y., Gupta, S., Jensen, P., Wartmann, M., Davis, R. J., and Kelly, K. (1994) Nature 367,651-654 [CrossRef][Medline] [Order article via Infotrieve]
  39. Osterop, A. P. R. M., Medema, R. H., v. d. Zon, G. C. M., Bos, J. L., Möller, W., and Maassen, J. A. (1993) Eur. J. Biochem. 212,477-48 [Abstract]
  40. Cherniack, A. D., Klarlund, J. K., Conway, B. R., and Czech, M. P. (1995) J. Biol. Chem. 270,1485-1488 [Abstract/Free Full Text]
  41. Waters, S. B., Yamauchi, K., and Pessin, J. E. (1995) Mol. Cell. Biol. 15,2791-2799 [Abstract]
  42. Clancy, B. M., and Czech, M. P. (1990) J. Biol. Chem. 265,12434-12443 [Abstract/Free Full Text]
  43. Shisheva, A., Buxton, J., and Czech, M. P. (1994) J. Biol. Chem. 269,23865-23868 [Abstract/Free Full Text]
  44. Farnsworth, C. L., Marshall, M. S., Gibbs, J. B., Stacey, D. W., and Feig, L. A. (1991) Cell 64,625-633 [Medline] [Order article via Infotrieve]
  45. Bradford, M. M. (1976) Anal. Biochem. 72,248-254 [CrossRef][Medline] [Order article via Infotrieve]
  46. Knutson, V. P. (1992) J. Biol. Chem. 267,931-937 [Abstract/Free Full Text]
  47. Rozakis-Adcock, M., McGlade, J., Mbamalu, G., Pelicci, G., Daly R. D., Li, W., Batzer, A. G., Thomas, S., Brugge, J., Pelicci, P. G., Schlessinger, J., and Pawson, T. (1992) Nature 360,689-692 [CrossRef][Medline] [Order article via Infotrieve]
  48. Kazlauskas, A. (1994) Curr. Opin. Gen. Dev. 4,5-14 [Medline] [Order article via Infotrieve]
  49. Robinson, L. J., Razzack, Z. F., Lawrence, J. C., Jr., and James, D. E. (1993) J. Biol. Chem. 268,26422-26427 [Abstract/Free Full Text]
  50. Simpson, I. A., Yver, D. R., Hissin, P. J., Wardzala, L. J., Karnieli, E., Salans, L. B., and Cushman, S. W. (1983) Biochim. Biophys. Acta 763,393-407 [Medline] [Order article via Infotrieve]
  51. Chang, C.-P., Lazar, C. S., Walsh, B. J., Komuro, M., Collawn, J. F., Kuhn, L. A., Tainer, J. A., Trowbridge, I. S., Farquhar, M. G., Rosenfeld, M. G., Wiley, H. S., and Gill, G. N. (1993) J. Biol. Chem. 268,19312-19320 [Abstract/Free Full Text]
  52. Decker, S. J., Alexander, C., and Habib, T. (1992) J. Biol. Chem. 267,1104-1108 [Abstract/Free Full Text]
  53. Felder, S., LaVin, J., Ullrich, A., and Schlessinger, J. (1992) J. Cell Biol. 117,203-212
  54. Hart, C. E., Forstrom, J. W., Kelly, J. D., Seifert, R. A., Smith, R. A., Ross, R., Murray, M. J., and Bowen-Pope, D. F. (1988) Science 240,1529-1531 [Medline] [Order article via Infotrieve]
  55. Heisermann, G. J., Wiley, H. S., Walsh, B. J., Ingraham, H. A., Fiol, C. J., and Gill, G. N. (1990) J. Biol. Chem. 265,12820-12827 [Abstract/Free Full Text]
  56. Heldin, C.-H., Wasteson, A., and Westermark, B. (1982) J. Biol. Chem. 257,4216-4221 [Abstract/Free Full Text]
  57. Lund, K. A., Lazar, C. S., Chen, W. S., Walsh, B. J., Welsh, J. B., Herbst, J. J., Walton, G. M., Rosenfeld, M. G., Gill, G. N., and Wiley, H. S. (1990) J. Biol. Chem. 265,20517-20523 [Abstract/Free Full Text]
  58. McCune, B. K., Prokop, C. A., and Earp, H. S. (1990) J. Biol. Chem. 265,9715-9721 [Abstract/Free Full Text]
  59. Wiley, H. S., Herbst, J. J., Walsh, B. J., Lauffenburger, D. A., Rosenfeld, M. G., and Gill, G. N. (1991) J. Biol. Chem. 266,11083-11094 [Abstract/Free Full Text]
  60. Arsenis, G., Hayes, G. R., and Livingston, J. N. (1985) J. Biol. Chem. 260,2202-2207 [Abstract]
  61. Marshall, S., Green, A., and Olefsky, J. M. (1981) J. Biol. Chem. 256,11464-11470 [Free Full Text]
  62. Giorgetti, S., Pelicci, P. G., and Van Obberghen, E. (1994) Eur. J. Biochem. 223,195-202 [Abstract]
  63. Pelicci, G., Lanfrancone, L., Grignani, F., McGlade, J., Cavallo, F., Forni, G., Nicoletti, I., Grignani, F., Pawson, T., and Pelicci, P. G. (1992) Cell 70,93-104 [Medline] [Order article via Infotrieve]
  64. Pronk, G. J., de Vries-Smits, A. M. M., Buday, L., Downward, J., Maassen, J. A., Medema, R. H., and Bos, J. L. (1994) Mol. Cell. Biol. 14,1575-1581 [Abstract]
  65. Skolnik, E. Y., Lee, C. H., Batzer, A. G., Vincentini, L. M., Zhou, M., Daly, R., Myers, M. J., Jr., Backer, J. M., Ullrich, A., White, M. F., and Schlessinger, J. (1993) EMBO J. 12,1929-1936 [Abstract]
  66. Soler, C., Alvarez, C. V., Beguinot, L., and Carpenter, G. (1994) Oncogene 9,2207-2215 [Medline] [Order article via Infotrieve]
  67. Gotoh, N., Tojo, A., Muroya, K., Hashimoto, Y., Hattori, S., Nakamura, S., Takenawa, T., and Shibuya, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91,167-171 [Abstract]
  68. Burgering, B. M., Pronk, G. J., van Weeren, P. C., Chardin, P., and Bos, J. L. (1993) EMBO J. 12,4211-4220 [Abstract]
  69. Rozakis-Adcock, M., Fernley, R., Wade, J., Pawson, T., and Bowtell, D. (1993) Nature 363,83-85 [CrossRef][Medline] [Order article via Infotrieve]
  70. Cherniack, A. D., Klarlund, J. K., and Czech, M. P. (1994) J. Biol. Chem. 269,4717-4720 [Abstract/Free Full Text]
  71. Gross, E., Goldberg, D., and Levitzki, A. (1992) Nature 360,762-765 [CrossRef][Medline] [Order article via Infotrieve]
  72. Tanaka, S., Morishita, T., Hashimoto, Y., Hattori, S., Nakamura, S., Shibuya, M., Matuoka, K., Takenawa, T., Kurata, T., Nagashima, K., and Matsuda, T. (1994 ) Proc. Natl. Acad. Sci. U. S. A. 91,3443-3447

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.